Bristol’s “Underperforming” Mead Johnson, OTCs Could Be Shown The Door

Mead Johnson's sluggish sales, coupled with the low margins of nutritionals relative to pharmaceuticals, could make the Bristol-Myers Squibb unit ripe for divestiture or spin-off as the parent company seeks to restore Wall Street's confidence in its stock following a poor 2001 showing